Introduction/Background Advanced cervical cancer (ACC) continues to represent a significant cause of morbidity and mortality worldwide. The GOG-240 trial indicated that anti-angiogenesis therapy can have clinically meaningful therapeutic benefit in this population. However, the population represented in the trial was the ‘healthiest’ cohort of a population with poor prognosis. We analyzed our experience and outcomes in terms of efficacy and safety of bevacizumab in patients with ACC to obtain real-world data.

Methodology This is a cross-sectional retrospective study of patients with ACC treated with carboplatin plus paclitaxel for 6–10 cycles and bevacizumab every 3 weeks up to progression or unacceptable toxicity in three Portuguese institutions, between April 2016 and December 2022. Clinicopathological data and clinical outcomes were extracted from medical records. Response rates were determined according to RECIST 1.1 criteria.

Results Eighteen patients were included, with a median age of 58 years-old [34–77]. Thirteen presented ECOG PS 0, the remaining ECOG PS 1. Three patients had recurrent/persistent disease, 83,3% had metastatic disease at diagnosis . Ten patients had previously received cisplatin, 7 with radiotherapy. All of them had pelvic disease at the beginning of treatment. Median cycles of Carboplatin-paclitaxel were 8 [6–10]. Median cycles of bevacizumab were 13 [5–43]. Thirteen patients suspended treatment due to disease progression, five due to G3 toxicity. Of these, 3 patients presented complete response. Two patients had fistula G3, both had performed chemoradiotherapy (radiotherapy dose of 50.4 Gy in 28 fractions). Seven patients died but none due to treatment. The median Progression Free Survival and Overall Survival were 10,5 [3–79] and 32,5 months [6–87], respectively.

Conclusion We believe that, despite its limitations, this study can provide useful information and encouraging evidence that the routine use of bevacizumab as part of first-line treatment of patients with ACC may be associated with outcomes comparable with those obtained in GOG-240 study.

Disclosures Nothing to declare.